Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | AOC2 | O75106 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11940773 | 0.82 | HTR1B (0.47) | KDM4ECYP1A2MEN1KMT2ARAB9A | |
| SCHEMBL9270 | 0.80 | TSHR (0.46) | KDM4ECYP1A2MEN1KMT2ATSHR | |
| SCHEMBL23050 | 0.76 | CA1 (0.55) | KDM4ECYP1A2MEN1KMT2ATSHR | |
| SCHEMBL1638392 | 0.76 | CA1 (0.62) | KDM4ECYP1A2KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL10000602 | 0.74 | KDM4E (0.38) | KDM4ECYP1A2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL410485 | 0.73 | GAA (0.54) | KDM4EKMT2ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL3437802 | 0.73 | ALDH1A1 (0.42) | KDM4ECYP1A2TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL11959678 | 0.73 | TSHR (0.49) | KDM4ECYP1A2MEN1KMT2ATSHR | |
| SCHEMBL16437062 | 0.73 | L3MBTL1 (0.55) | CYP1A2ALDH1A1GLAALOX15NPSR1 | |
| SCHEMBL18017367 | 0.73 | SMN1; SMN2 (0.42) | KDM4EMEN1KMT2ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| CN-120035582-A | Pyridazinone compounds for the treatment of respiratory diseases | 病童医院 | 2025-05-23 | — | — | CN | disclosed |
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118702672-A | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-12024536-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118206455-A | Amine-containing compound, light-emitting device, electronic apparatus, and electronic device | 三星显示有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-8237002-B2 | Method for producing unsaturated organic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120012824-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2012-01-19 | — | — | US | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110046380-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | KDM4E 648/4885CYP1A2 1446/4885MEN1 1516/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KDM4E 3666/4885CYP1A2 146/4885MEN1 186/4885 |
| US-20120012824-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | AP1M1, MT-CO1, AP2M1 | KDM4E 3600/4885CYP1A2 471/4885MEN1 123/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | KDM4E 3979/4885CYP1A2 1677/4885MEN1 1094/4885 |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | KDM4E 1548/4885CYP1A2 147/4885MEN1 633/4885 |
| US-12024536-B2 | C-terminal HSP90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | KDM4E 4110/4885CYP1A2 4845/4885MEN1 4746/4885 |
| US-20110046380-A1 | METHOD FOR PRODUCING UNSATURATED ORGANIC COMPOUND | NIT2, NOS1, CHRM1 | KDM4E 4610/4885CYP1A2 212/4885MEN1 65/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | KDM4E 2050/4885CYP1A2 4692/4885MEN1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.